Global Cardiac Safety Services Market Report 2022 to 2027: Growth in Biosimilars and Biologics Markets Presents Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The cardiac safety services market is projected to reach USD 1.0 Billion by 2027 from USD 0.6 Billion in 2022, at a CAGR of 11.2% during the forecast period.

The Blood Pressure Measurement segment accounted for the second largest share of the type of services market in 2021

Blood pressure monitoring is an essential part of cardiac safety services. Increasing R&D activities and stringent clinical trial regulations make blood pressure measurement a critical parameter from both an efficacy and a safety endpoint. This factor is expected to drive the growth of this market segment.

The contract research organizations (CROs) accounted for the second largest share of the end user market in 2021

CROs provide specialized services to pharmaceutical & biopharmaceutical companies at a low cost. As a result, many pharmaceutical & biopharmaceutical companies are outsourcing their drug discovery services to CROs. As cardiac safety services are critical in drug development processes, their adoption is expected to increase with an increase in outsourcing

Laboratory Corporation of America Holdings (US), Koninklijke Philips N.V. (Netherlands), Clario (US), Banook Group (France), IQVIA (US), Biotrial (France), Certara (US), Celerion (US), Medpace (US), Ncardia (Netherlands), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon (China), Pharmaceutical Product Development (US), and SGS (Switzerland) are some of the major players operating in the market.

Europe: The second largest share in the cardiac safety services market

The European market includes Germany, the UK, France, Italy, Spain, and the RoE. It accounted for the second largest market share of the cardiac safety services market. Important considerations include demographic changes, such as the growing incidence of chronic diseases is expected to drive the market growth in the region

Market Dynamics

Drivers

• Growing R&D Expenditure in the Pharmaceutical & Biopharmaceutical Industry
• Increased Outsourcing of R&D Activities
• Increasing Number of Clinical Trials

Opportunities

• Introduction of New Technologies and Methods
• Growth in Biosimilars and Biologics Markets

Challenges

• High Cost of Cardiac Safety Evaluation

Companies Mentioned

• Banook Group
• Biotrial
• Clario
• Certara
• Celerion
• Iqvia
• Koninklijke Philips
• Laboratory Corporation of America Holdings
• Medpace
• Ncardia
• Physiostim
• Pharmaceutical Product Development LLC.
• Richmond Pharmacology
• Shanghai Medicilon
• SGS SA

For more information about this report visit https://www.researchandmarkets.com/r/wz9hiu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900